With limited regulations for clinical practice, screening for major viruses such as HIV, TB, and HBV (especially for patients with HCC) according to the prevalence before initiation of PD-1/PD-L1 blockade is encouraged (Reungwetwattana and Adjei, 2016; He et al., 2018). This evidence concerns the gene PDCD1 and tuberculosis.